-
Sep 6, 2024 | 
onclive.com | Jason Fangusaro
The leaders in the pediatric low-grade glioma (pLGG) field offer their concluding insights and perspectives on the future of pLGG management.
-
Sep 6, 2024 | 
onclive.com | Jason Fangusaro
OpinionVideoSeptember 6, 2024Author(s):The panel of pediatric low-grade glioma (pLGG) experts delves into the potential adverse events associated with targeted therapies, outlining common reactions and their severity, while also sharing their strategies and best practices for toxicity management. What are some of the common AEs seen in this patient population across the various treatment options (chemotherapy, radiation therapy, targeted therapy)?
-
Aug 30, 2024 | 
onclive.com | Jason Fangusaro
The key opinion leaders analyze a second clinical scenario, focusing on a patient with a BRAF V600E mutation in their pediatric low-grade glioma (pLGG).
-
Aug 30, 2024 | 
onclive.com | Jason Fangusaro
The panel presents alternative treatment options and key considerations for the discussed clinical scenario, elaborating on the factors that influence their decision-making process.
-
Aug 23, 2024 | 
onclive.com | Jason Fangusaro
OpinionVideoAugust 23, 2024Author(s):The panel examines a specific patient case, offering detailed insights into their decision-making process and treatment approaches for patients with pediatric low-grade gliomas (pLGG). Of the possible options, what treatment approach would you select for this patient? What key clinical or patient-specific factors informed this choice?
-
Aug 23, 2024 | 
onclive.com | Jason Fangusaro
Clinical Trials to Increase Treatment Options in the Progressive SettingThe panel reviews ongoing clinical trials aimed at expanding treatment options for progressive pediatric low-grade gliomas (pLGG), with a specific focus on the PNOC021, PBTC-055, and NF111 studies, discussing their objectives, design features, and potential impact on future treatment strategies.
-
Aug 16, 2024 | 
onclive.com | Jason Fangusaro
The Role of Tovorafenib in Treatment of Progressive pLGGThe panel reviews ongoing clinical trials aimed at expanding treatment options for progressive pediatric low-grade gliomas (pLGG), with a specific focus on the PNOC021, PBTC-055, and NF111 studies, discussing their objectives, design features, and potential impact on future treatment strategies.
-
Aug 16, 2024 | 
onclive.com | Jason Fangusaro
The panel of medical experts examines the roles of radiation therapy and targeted therapies in the management of progressive pediatric low-grade gliomas (pLGG).
-
Aug 9, 2024 | 
onclive.com | Jason Fangusaro
Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGGThe panel explores the standard of care options tailored specifically for the frontline treatment of pediatric low-grade gliomas (pLGG) harboring the BRAF V600E mutation, discussing current best practices and targeted therapeutic approaches.
-
Aug 2, 2024 | 
onclive.com | Jason Fangusaro
The panel reviews ongoing clinical trials for non-BRAF V600E pediatric low-grade gliomas (pLGG), specifically highlighting the Phase III ACNS1831 and Phase III ACNS1833 studies, discussing their objectives, designs, and potential implications for future treatment strategies.
